1093951-66-6 Usage
General Description
2-Methoxy-4-methyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine is a chemical compound that is commonly used as a catalyst in various organic synthesis reactions. It is a pyridine-based compound with a boron-containing substituent, making it a valuable reagent in the field of organic chemistry. 2-Methoxy-4-methyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine is known for its ability to facilitate a range of important chemical reactions, including cross-coupling reactions and metal-catalyzed transformations. Its unique structural and electronic properties make it essential for the development of novel and efficient synthetic methodologies. Additionally, it has potential applications in pharmaceutical and agrochemical industries for the production of various complex organic molecules.
Check Digit Verification of cas no
The CAS Registry Mumber 1093951-66-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,3,9,5 and 1 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1093951-66:
(9*1)+(8*0)+(7*9)+(6*3)+(5*9)+(4*5)+(3*1)+(2*6)+(1*6)=176
176 % 10 = 6
So 1093951-66-6 is a valid CAS Registry Number.
1093951-66-6Relevant articles and documents
NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS
-
Paragraph 0335-0336, (2020/11/03)
Disclosed are compounds of formula (I) or (II) that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
PRC2 INHIBITORS
-
Paragraph 0285-0286, (2019/08/26)
The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention. (Formula (I))
TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF
-
Paragraph 0346; 0351; 0355; 0357, (2016/07/27)
A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
